Weekly Issue — 2026-02-08

Most dietary trials struggle with a basic problem: people are bad at sticking to assigned diets, and the people who do stick tend to differ from those who don't. Religious fasting traditions sidestep that. Practitioners adopt the same restriction at the same time, for reasons that have nothing to do with cholesterol or glucose, and then return — just as reliably — to their usual eating. The Greek Orthodox calendar, with its alternating fast and feast periods, effectively turns each practitioner into their own control.

That is the design researchers leaned on in a 2025 paper in npj Metabolic Health and Disease, which compared plasma metabolomic and proteomic profiles across dietary states in this population and against a non-fasting comparison group. The signal they were looking for was not weight loss or a single headline biomarker, but a pattern: which molecules move, in which direction, and whether they move together in a way that maps onto known cardiometabolic risk. Short-term restriction, they reported, drove reductions in lipid classes and branched-chain amino acids that were not detected in the control group.

Two of the moved categories are worth dwelling on. Circulating lipids — the broad family that includes cholesterol-carrying particles and various fats in the blood — are central to cardiovascular risk modeling. Branched-chain amino acids (BCAAs: leucine, isoleucine, valine) are essential nutrients, abundant in animal protein, that have drawn attention in metabolic research because elevated levels tend to track with insulin resistance and type 2 diabetes risk in population studies. A coordinated downshift in both, after a defined dietary change, is the kind of pattern that catches a metabolic researcher's eye.

The authors went further, comparing the post-restriction profile against signatures previously linked to mortality risk in larger cohorts. The restriction state produced metabolic profiles associated with decreased risk for all-cause mortality. That is an association, not a clinical outcome — nobody followed these fasters for decades — but it is a meaningful direction of travel for a short-term intervention.

Beyond small molecules, the team profiled plasma proteins — the workhorses and messengers of physiology — and found that the dietary switch moved a substantial slice of them. Roughly 23% of the proteins whose levels shifted with restriction are considered druggable targets, meaning the pharmaceutical world already has, or could plausibly build, molecules that act on them. Among the largest movers was FGF21, a hormone that has attracted interest as a regulator of energy balance and metabolic stress, alongside seven others: FOLR2, SUMF2, HAVCR1, PLA2G1B, OXT, SPP1 and HPGDS.

Using Mendelian randomization — a genetic technique that helps probe whether an association is likely causal — the authors went one step further. They reported potentially causal effects of FGF21 and HAVCR1 on type 2 diabetes risk, of HPGDS on BMI, and of OXT on risk for lacunar stroke. The implication is intriguing: some of the proteins responding to a plant-forward window may be mechanistically tied to outcomes that matter, not merely along for the ride.

It is tempting, especially for readers who like a clean protocol, to translate this into a prescription: fast like a monk, four times a year, and watch your blood chemistry improve. The evidence does not yet support that leap. The study is observational in design, even if elegantly so; the fasting population differs culturally and behaviorally from the average reader; the time horizons are short; and metabolic shifts in the blood are not the same as long-term clinical outcomes. The editorial read here is moderate-evidence: a credible, mechanistically coherent signal that periodic plant-forward eating reshapes the metabolome in cardiometabolically favorable ways, worth taking seriously without overreading.

What the work does do — quietly but importantly — is push back against the framing that diets must be permanent to matter. The fasters in this study were not lifelong vegetarians. They moved in and out of animal-product restriction on a calendar, and their plasma chemistry moved with them. That cyclical pattern is unusual in modern nutrition research, and it hints that the body may respond to dietary structure, not just dietary identity.

For busy readers tracking the cardiometabolic literature, the takeaway is less about Orthodox practice specifically and more about what it reveals. Short, structured periods of plant-forward eating appear to produce a coordinated downshift in lipids and BCAAs, a measurable reshuffling of the plasma proteome, and a profile that — at the level of pattern, not promise — looks like the kind associated with longer, healthier lives. The mechanisms are starting to come into focus. The clinical translation, including whether discrete fasting-style windows can match the benefits of continuous Mediterranean-style eating, is still being written.

In the meantime, the most useful posture is the one this research itself models: curious, methodical, and respectful of the difference between a beautiful signal and a settled answer.

Number needed to treat is the unglamorous metric that separates a press release from a real drug. It answers: how many people have to take this thing, for how long, to prevent one bad event? The meta-analysis ran that calculation across an average follow-up of about three and a half years and landed on figures that are, by cardiology standards, genuinely good.

To prevent one heart attack, 207 patients need to be treated. To prevent one major adverse cardiovascular event — the composite of MI, stroke and cardiovascular death that regulators care about — the NNT drops to 67. Cardiovascular mortality alone: 170. Stroke: 335. For context, statins in primary prevention typically post NNTs in the same neighborhood for MACE over similar timeframes. GLP-1RAs are now playing in that league, and they are doing it in a population that often cannot tolerate or fully benefit from statins alone.

The meta-analysis flagged a meaningful effect modifier: higher BMI was associated with greater MI risk reduction in GLP-1RA users (β: -0.09, p = 0.03). Translated: the further someone sits from a healthy body composition, the more cardiac upside the drug appears to deliver. This is consistent with the biology — these molecules act on weight, glycemia, blood pressure and inflammation simultaneously — but it is also a useful filter for the busy 40-year-old asking whether this conversation applies to him.

If you are lean, metabolically healthy and have no family history of premature ASCVD, the absolute benefit on display in these trials is small. If you carry significant visceral adiposity, prediabetes or type 2 diabetes, or established cardiovascular risk, the same relative risk reduction translates into a much larger absolute payoff. The drug is not a generic longevity tool. It is a cardiometabolic intervention whose value tracks your starting risk.

Importantly, the cardiovascular benefit held across patients with and without type 2 diabetes. That matters. It moves GLP-1RAs out of the diabetes silo and into a broader cardioprotective conversation — one that primary-care physicians and cardiologists are now having in real time.

Standard lipid panels are a blunt instrument. Two men with identical LDL-C numbers can carry very different atherosclerotic risk depending on the size and density of their lipoprotein particles — small, dense LDL is the troublemaker. A 52-week randomized trial published this year went looking at that finer-grained picture in patients with type 2 diabetes.

The trial randomized 34 obese T2D patients to weekly subcutaneous semaglutide or daily oral sitagliptin, with 31 non-diabetic obese controls. After a year, semaglutide produced significant reductions in BMI, waist circumference and HbA1c, alongside lower LDL cholesterol and non-HDL cholesterol and a redistribution of LDL and HDL subfractions toward a less atherogenic profile. Sitagliptin moved glycemia modestly and barely touched the lipid composition.

The mechanistic kicker: multivariate regression suggested the lipoprotein shifts were not simply downstream of weight loss or glycemic improvement. Something else — a direct pleiotropic effect of GLP-1 signaling on lipid handling — appears to be doing work. The sample is small and the population specific, so caution is warranted before extrapolating. But it is a coherent piece of evidence alongside the meta-analysis: better lipid quality, not just a lower number on the scale.

None of this is free. The same meta-analysis quantified the cost: GLP-1RAs roughly increased gastrointestinal side effects by 55% versus placebo, with a number-needed-to-harm of 9 for GI events. Nausea, reflux, constipation, the early-titration tax everyone on these drugs knows about. For most patients these symptoms attenuate, but they are not rare and they are the main reason people quit.

What the trial data does not tell you is how the math shifts at lower, off-label or recreational doses, or in lean people chasing modest cosmetic weight loss. The MACE numbers come from patients with elevated cardiovascular risk treated to therapeutic doses for years. Anyone considering a GLP-1RA — particularly for cardiovascular prevention rather than diabetes — should have that conversation with a clinician who can weigh personal risk against the trade-offs honestly.

For the reader sizing this up against squat numbers and resting heart rate: the meta-analysis does not make GLP-1RAs a default biohack. It makes them a serious cardiovascular drug for people with serious cardiovascular risk. If your waist circumference, fasting glucose, ApoB or family history puts you in that bucket, the case is now strong enough to put on a clinician's desk and discuss explicitly — alongside lifestyle work that no injectable replaces. If you are metabolically tidy and chasing the last five pounds, the risk-benefit math from these trials simply does not apply to you.

The bigger shift is conceptual. We are watching a class of peptides graduate from weight-loss drugs to cardiometabolic drugs, with the trial evidence to back the new label. That is the rarer kind of medical news: not a hype cycle, but a recalibration.

The shift is partly a success story. Pediatric RSV deaths have fallen meaningfully over time thanks to better supportive care and, more recently, monoclonal antibodies for infants. But the other half of the story is demographic and biological. Populations are older. Immune systems age. And RSV, it turns out, is a serious lower-respiratory pathogen in anyone whose lungs, heart, or immune defenses are already working harder than they used to.

What's new in 2025 is not the virus. It's the toolkit. Three adult RSV vaccines — RSVPreF3, RSVpreF, and the mRNA-based mRNA-1345 — have now been approved for adult use, the first time older adults have had any specific preventive option against a virus for which, the same review emphasizes, there is still no specific treatment in adults. That last point is the one worth sitting with. For RSV in a 75-year-old with COPD or heart failure, the medical playbook is oxygen, fluids, and time.

RSV is a leading cause of lower respiratory tract infections worldwide, and the review frames it bluntly as a major health threat especially for children and older adults. The under-5 burden has been studied for generations; the older-adult burden has been hiding in plain sight, often misclassified as influenza, pneumonia, or a vague "viral exacerbation" of an underlying condition. Better diagnostics have pulled it into focus.

The biology is unforgiving in older lungs. RSV inflames the small airways, and small airways in a 70-year-old don't recover the way they do in a toddler. Layer on common comorbidities — chronic obstructive pulmonary disease, congestive heart failure, diabetes, immune suppression from cancer therapy — and a virus most people would shrug off becomes a hospitalization, sometimes a fatal one. The review situates this within a broader pattern: as pediatric deaths fall, RSV appears increasingly significant for the elderly and adults with underlying health conditions.

The three approved adult vaccines take different technical routes to the same target: the RSV fusion protein in its pre-fusion shape, the configuration the virus uses to enter human cells. RSVPreF3 and RSVpreF are protein-based; mRNA-1345 uses messenger RNA, the same platform familiar from COVID-19 vaccines. All three are approved for adults, and the review's stated purpose is to summarize the safety and efficacy evidence behind them.

The honest framing is that this is a moderate-confidence moment. The evidence base is real and growing, the regulatory bar has been cleared in multiple jurisdictions, and the public-health rationale — a serious disease with no specific treatment and a clearly identified at-risk population — is straightforward. What remains less settled, and what readers should expect to see refined over the next several seasons, is the durability of protection, the optimal interval between doses, and how the three vaccines compare head-to-head in the populations that need them most.

A predictable side effect of any new adult vaccine category is a wave of adjacent marketing: immune-boosting lozenges, "lung support" botanicals, megadose vitamin stacks pitched at exactly the demographic the vaccines target. None of that is what the evidence in this review is about. The cited paper is a synthesis of epidemiology and vaccine data, not a verdict on supplements, and nothing in it suggests an over-the-counter substitute for a vaccine against a virus with no specific treatment.

The cleaner read is that RSV has joined influenza and pneumococcal disease on the short list of respiratory threats with both a defined at-risk adult population and a specific preventive tool. Whether any individual reader is in that population — and which of the three vaccines, if any, fits — is a clinical conversation, not a checkout-aisle one.

The RSV story is a small case study in something larger: the diseases of healthy aging are not the diseases of midlife with a few extra wrinkles. They are, often, different diseases — or familiar diseases behaving differently because the host has changed. The same review notes the situation in low- and middle-income countries, where aging populations and constrained vaccine access will shape who actually benefits from this new category over the next decade.

For now, the practical takeaway is narrow and defensible. RSV is a meaningful adult risk, especially after 70 and especially with chronic illness. Three vaccines exist where none did a few years ago. The evidence supporting them is moderate and improving. And the right next step, for anyone seeing themselves in this picture, is a conversation with a clinician — not a new bottle on the shelf.